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ABSTRACT 
Genome-wide association studies (GWAS) have transformed our understanding of susceptibility 
to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new 
GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9,974 MM cases 
and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new 
MM risk loci, bringing the total number to 23. Integration of information from gene expression, 
epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of 
developmental transcriptional regulators as a basis of MM susceptibility, compatible with 
altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and 
cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further 
insight into the biological basis of MM. 
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INTRODUCTION 
 
Multiple myeloma (MM) is a malignancy of plasma cells primarily located within the bone marrow. 
Although no lifestyle or environmental exposures have been consistently linked to an increased 
risk of MM, the two- to four-fold increased risk observed in relatives of MM patients provides 
support for inherited genetic predisposition1. Our understanding of MM susceptibility has recently 
been informed by genome-wide association studies (GWAS), which have so far identified 17 
independent risk loci for MM2-5, with an additional locus being subtype-specific for t(11;14) 
translocation MM6. Much of the heritable risk of MM, however, remains unexplained and 
statistical modelling indicates that further common risk variants remain to be discovered7. 
 
To gain a more comprehensive insight into MM aetiology, we performed a new GWAS followed by 
a meta-analysis with existing GWAS and replication genotyping (totalling 9,974 cases and 247,556 
controls). Here we report the identification of six new MM susceptibility loci as well as refined risk 
estimates for the previously reported loci. In addition, we have investigated the possible gene 
regulatory mechanisms underlying the associations seen at all 23 GWAS risk loci by analysing in 
situ promoter Capture Hi-C (CHi-C) in MM cells to characterize chromatin interactions between 
predisposition single nucleotide polymorphism (SNPs) and target genes, integrating these data 
with chromatin immunoprecipitation-sequencing (CHiP-seq) data generated in house and a range 
of publicly available genomics data. Finally, we have quantified the contribution of both new and 
previously discovered loci to the heritable risk of MM and implemented a likelihood-based 
approach to estimate sample sizes required to explain 80% of the heritability.  
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RESULTS 
 
Association analysis 
We conducted a new GWAS using the OncoArray platform8 (878 MM cases and 7,083 controls 
from the UK), followed by a meta-analysis with six published MM GWAS data sets (totalling 7,319 
cases and 234,385 controls) (Fig. 1, Supplementary Tables 1-3)2-5. To increase genomic resolution, 
we imputed data to >10 million SNPs. Quantile-quantile (Q-Q) plots for SNPs with minor allele 
frequency (MAF) >1% after imputation did not show evidence of substantive over-dispersion for 
the OncoArray GWAS (λ = 1.03, λ1000=1.02, Supplementary Fig. 1). We derived joint odds ratios 
(ORs) under a fixed-effects model for each SNP with MAF >1%. Finally, we sought validation of 
nine SNPs associated at P < 1 × 10−6 in the meta-analysis, which did not map to known MM risk loci 
and displayed a consistent OR across all GWAS data sets, by genotyping an additional 1,777 cases 
and 6,088 controls from three independent series (Germany, Denmark and Sweden). After meta-
analysis of the new and pre-existing GWAS data sets and replication series, we identified genome-
wide significant associations (i.e. P < 5 × 10−8)9 for six new loci at 2q31.1, 5q23.2, 7q22.3, 7q31.33, 
16p11.2 and 19p13.11 (Table 1, Supplementary Table 4 and 5, Fig. 2). Additionally, borderline 
associations were identified at two loci with P-values of 5.93 × 10-8 (6p25.3) and 9.90 × 10-8 
(7q21.11), which have corresponding Bayesian false-discovery probabilities10 of 4% and 6%, 
respectively (Supplementary Table 4 and 5). We found no evidence for significant interactions 
between any of the 23 risk loci. Finally, we found no evidence to support the existence of the 
putative risk locus at 2p12.3 (rs1214346), previously proposed by Erickson et al 11(GWAS meta-
analysis P-value = 0.32).  
 
Risk SNPs and myeloma phenotype 
We did not find any association between sex or age at diagnosis and the 23 MM risk SNPs using 
case-only analysis (Supplementary Table 6 and 7). Aside from previously reported relationships 
between the risk loci at 11q13.3 and 5q15 with t(11;14) MM6 and hyperdiploid MM12, 
respectively, we found no evidence for subtype-specific associations (Supplementary Table 8-11) 
or an impact on MM-specific survival (Supplementary Table 12). A failure to demonstrate 
additional relationships may, however, be reflective of limited study power. Collectively, these 
data suggest that the risk variants are likely to have generic effects on MM development. 
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Contribution of risk SNPs to heritability 
Using Linkage Disequilibrium Adjusted Kinships (LDAK)13, the heritability of MM ascribable to all 
common variation was 15.6% (±4.7); collectively the previously identified and new risk loci account 
for 15.7% of the GWAS heritability (13.6% and 2.1% respectively). To assess the collective impact 
of all identified risk SNPs we constructed polygenic risk scores (PRS) considering the combined 
effect of all risk SNPs modelled under a log-normal relative risk distribution14. Using this approach, 
an individual in the top 1% of genetic risk has a 3-fold increased risk of MM when compared to an 
individual with median genetic risk (Supplementary Fig. 2). We observed an enrichment of risk 
variants among familial MM compared with both sporadic MM cases and population-based 
controls comparable to that expected in the absence of a strong monogenic predisposition 
(respective P-values 0.027 and 1.60 x 10-5; Supplementary Fig. 3). Undoubtedly, the identification 
of further risk loci through the analysis of larger GWAS are likely to improve the performance of 
any PRS model. To estimate the sample size required to explain a greater proportion of the GWAS 
heritability, we implemented a likelihood-based approach using association statistics in 
combination with LD information to model the effect-size distribution15,16. The effect-size 
distributions for susceptibility SNPs were best modelled using the three-component model 
(mixture of two normal distributions) (Supplementary Fig. 4). Under this model, to identify SNPs 
explaining 80% of the GWAS heritability is likely to require sample sizes in excess of 50,000 
(Supplementary Fig. 5).  
 
Functional annotation and biological inference of risk loci 
To the extent that they have been studied, many GWAS risk SNPs localise to non-coding regions 
and influence gene regulation17. To investigate the functional role of previously reported and new 
MM risk SNPs we performed a global analysis of  SNP associations using ChIP-seq data generated 
on the MM cell line KMS11 and publicly accessible naïve B-cell Blueprint Epigenome Project data18. 
We found enrichment of MM SNPs in regions of active chromatin, as indicated by the presence of 
H3K27ac, H3K4Me3 and H3K4Me1 marks (Supplementary Fig. 6). We also observed an 
enrichment of relevant B-cell transcription factor (TF) binding sites using ENCODE GM12878 
lymphoblastoid cell line data (Supplementary Fig. 7). Collectively these data support the tenet 
that the MM predisposition loci influence risk through effects on cis-regulatory networks involved 
in transcriptional initiation and enhancement.  
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Since genomic spatial proximity and chromatin looping interactions are key to the regulation of 
gene expression, we interrogated physical interactions at respective genomic regions in KMS11 
and naïve B-cells using CHi-C data19. We also sought to gain insight into the possible biological 
mechanisms for associations by performing an expression quantitative trait locus (eQTL) analysis 
using mRNA expression data on CD138-purified MM plasma cells; specifically, we used Summary 
data-based Mendelian Randomization (SMR) analysis20 to test for pleiotropy between GWAS signal 
and cis-eQTL for genes within 1 Mb of the sentinel SNP to identify a causal relationship. We 
additionally annotated risk loci with variants mapping to binding motifs of B-cell specific TFs. 
Finally, we catalogued direct promoter variants and non-synonymous coding mutations for genes 
within risk loci (Table 2 and Fig. 1). 
 
Although preliminary, and requiring functional validation, our analysis delineates four potential 
candidate disease mechanisms across the 23 MM risk loci (Table 2). Firstly, four of the risk loci 
contain candidate genes linked to regulation of cell cycle and genomic instability, as evidenced by 
Hi-C looping interactions in KMS11 cells to MTAP (at 9p21.3) and eQTL effects for CEP120 (at 
5q23.2). CEP120 is required for microtubule assembly and elongation, with overexpression of 
CEP120 leading to uncontrolled centriole elongation21. rs58618031 (7q31.33) maps 5′ of POT1, the 
protection of telomeres 1 gene. POT1 is part of the shelterin complex that functions to protect 
telomeres and maintain chromosomal stability22,23. While mutated POT1 is not a feature of MM, it 
is commonly observed in B-cell chronic lymphocytic leukaemia24-26. The looping interaction from 
the rs58618031 annotated enhancer element implicates ASB15. Members of the ASB-family 
feature as protein components of the ubiquitin-proteasome system, intriguingly a therapeutic 
target in MM27-29. 
 
Second, candidate genes encoding proteins involved in chromatin remodelling were implicated at 
three of the MM risk loci, supported by promoter variants at 2q31.1, 7q36.1 and 22q13.1. The new 
locus at 2q31.1 implicates SP3, encoding a TF, which through promoter interaction, has a well-
established role in B-cell development influencing the expression of germinal centre genes, 
including activation-induced cytidine deaminase AID30,31.  
 
Third, the central role IRF4-MYC-mediated apoptosis/autophagy in MM oncogenesis is supported 
by variation at five loci, including eQTL effects WAC (at 10p12.1) and Hi-C looping interactions (at 
8q24.21 and 16q23.1). The 7p15.3 association ascribable to rs4487645 has been documented to 
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influence expression of c-MYC-interacting CDCA7L through differential IRF4 binding 32. Similarly, 
the long-range interaction between CCAT1 (colon cancer-associated transcript 1) and MYC 
provides an attractive biological basis for the 8q24.21 association, given the notable role of MYC in 
MM33,34. It is noteworthy that the promising risk locus at 6p25.3 contains IRF4. At the new locus 
19p13.11, the missense variant (NP_057354.1:p.Leu104Pro) and the correlated promoter SNP 
rs11086029 implicates KLF2 in MM biology. Demethylation by KDM3A histone demethylase 
sustains KLF2 expression and influences IRF4-dependent MM cell survival35. The new 16p11.2 risk 
locus contains a number of genes including Proline-Rich Protein 14 (PRR14), which is implicated in 
PI3-kinase/Akt/mTOR signalling, a therapeutic target in myelomatous plasma cells 36.  
 
Fourth, loci related to B-cell and plasma cell differentiation and function are supported by 
variation at three loci, including eQTL effects (ELL2 at 5q15) and Hi-C looping interactions (at 
6q21). As previously inferred from GM12878 cell line data, the region at 6q21 (rs9372120, ATG5) 
participates in intra-chromosome looping with the B-cell transcriptional repressor PRDM1 (alias 
BLIMP1)4.  Additionally, SNP rs34562254 at 17p11.2 is responsible for the amino acid substitution 
(NP_036584.1:p.Pro251Leu) in TNFRSF13B, a key regulator of normal B-cell homeostasis, which 
has an established role in MM biology37-42.  
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DISCUSSION 
 
Our meta-analysis of a new GWAS series in conjunction with previously published MM datasets 
has identified six novel risk loci. Together, the new and previously reported loci explain an 
estimated 16% of the SNP heritability for MM in European populations. Ancestral differences in 
the risk of developing MM are well recognised, with a greater prevalence of MM in African 
Americans as compared with those with European ancestry43. It is plausible that the effects of MM 
risk SNPs may differ between Europeans and non-Europeans and hence contribute to differences 
in prevalence rates. Thus far there has only been limited evaluation of this possibility with no 
evidence for significant differences44.  
 
Integration of Hi-C data with ChIP-seq chromatin profiling from MM and lymphoblastoid cell lines 
and naïve B-cells, and eQTL analysis, using patient expression data, has allowed us to gain 
preliminary insight into the biological basis of MM susceptibility. This analysis suggests a model of 
MM susceptibility based on transcriptional dysregulation consistent with altered B-cell 
differentiation, where dysregulation of autophagy/apoptosis and cell cycle signalling feature as 
recurrently modulated pathways. Specifically, our findings implicate mTOR-related genes ULK4, 
ATG5 and WAC, and by virtue of the role of IRF4-MYC related autophagy, CDCA7L, DNMT3A, CBX7 
and KLF2 in MM development (Table 2). Further investigations are necessary to decipher the 
functional basis of risk SNPs, nevertheless we highlight mTOR-signalling and the ubiquitin-
proteasome pathway, targets of approved drugs in MM. As a corollary of this, genes elucidated via 
the functional annotation of GWAS discovered MM risk loci may represent promising therapeutic 
targets for myeloma drug discovery. Finally, our estimation of sample sizes required to identify a 
larger proportion of the heritable risk of MM attributable to common variation underscore the 
need for further international collaborative analyses. 
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METHODS 
 
Ethics 
Collection of patient samples and associated clinico-pathological information was undertaken with 
written informed consent and relevant ethical review board approval at respective study centres 
in accordance with the tenets of the Declaration of Helsinki. Specifically for the Myeloma-IX trial 
by the Medical Research Council (MRC) Leukaemia Data Monitoring and Ethics committee (MREC 
02/8/95, ISRCTN68454111), the Myeloma-XI trial by the Oxfordshire Research Ethics Committee 
(MREC 17/09/09, ISRCTN49407852), HOVON65/GMMG-HD4 (ISRCTN 644552890; METC 
13/01/2015), HOVON87/NMSG18 (EudraCTnr 2007-004007-34, METC 20/11/2008), 
HOVON95/EMN02 (EudraCTnr 2009-017903-28, METC 04/11/10), University of Heidelberg Ethical 
Commission (229/2003, S-337/2009, AFmu-119/2010), University of Arkansas for Medical Sciences 
Institutional Review Board (IRB 202077), Lund University Ethical Review Board (2013/54), the 
Norwegian REK 2014/97, the Danish Ethical Review Board (no: H-16032570) and Icelandic Data 
Protection Authority (2,001,010,157 and National Bioethics Committee 01/015). 
 
The diagnosis of MM (ICD-10 C90.0) in all cases was established in accordance with World Health 
Organization guidelines. All samples from patients for genotyping were obtained before treatment 
or at presentation. 
 
Primary GWAS 
We analysed constitutional DNA (EDTA-venous blood derived) from 931 cases ascertained through 
the UK Myeloma XI trial; detailed in Supplementary Table 1. Cases were genotyped using the 
Illumina OncoArray (Illumina Inc. San Diego, CA 92122, USA). Controls were also genotyped using 
the OncoArray and comprised: (1) 2,976 cancer-free men recruited by the PRACTICAL Consortium - 
the UK Genetic Prostate Cancer Study (UKGPCS) (age <65 years), a study conducted through the 
Royal Marsden NHS Foundation Trust and SEARCH (Study of Epidemiology & Risk Factors in 
Cancer), recruited via GP practices in East Anglia (2003-2009), (2) 4,446 cancer-free women across 
the UK, recruited via the Breast Cancer Association Consortium (BCAC).  
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Standard quality-control measures were applied to the GWAS45. Specifically, individuals with low 
SNP call rate (<95%) as well as individuals evaluated to be of non-European ancestry (using the 
HapMap version 2 CEU, JPT/CHB and YRI populations as a reference) were excluded 
(Supplementary Fig. 8). For apparent first-degree relative pairs, we excluded the control from a 
case-control pair; otherwise, we excluded the individual with the lower call rate. SNPs with a call 
rate <95% were excluded as were those with a MAF <0.01 or displaying significant deviation from 
Hardy–Weinberg equilibrium (P < 10−5). GWAS data were imputed to >10 million SNPs using 
IMPUTE2 v2.346 software in conjunction with a merged reference panel consisting of data from 
1000 Genomes Project47 (phase 1 integrated release 3 March 2012) and UK10K48. Genotypes were 
aligned to the positive strand in both imputation and genotyping. We imposed predefined 
thresholds for imputation quality to retain potential risk variants with MAF >0.01 for validation. 
Poorly imputed SNPs with an information measure <0.80 were excluded. Tests of association 
between imputed SNPs and MM was performed under an additive model in SNPTESTv2.549. The 
adequacy of the case–control matching and possibility of differential genotyping of cases and 
controls was evaluated using a Q-Q plot of test statistics (Supplementary Fig. 1). The inflation λ 
was based on the 90% least-significant SNPs 50 and assessment of λ1000. Details of SNP QC are 
provided in in Supplementary Table 2. 
 
Published GWAS 
The data from six previously reported GWAS2-5 are summarized in Supplementary Table 1. All 
these studies were based on individuals with European ancestry and comprised: UK-GWAS (2,282 
cases, 5,197 controls), Swedish-GWAS (1,714 cases, 10,391 controls), German-GWAS (1,508 cases, 
2,107 controls), Netherlands-GWAS (555 cases, 2,669 controls), US-GWAS (780 cases, 1,857 
controls) and Iceland (480 cases, 212,164 controls).  
 
Replication studies and technical validation 
To validate promising associations, we analysed three case-control series from Germany, Sweden 
and Denmark, summarised in Supplementary Table 3. The German replication series comprised 
911 cases collected by the German Myeloma Study Group (Deutsche Studiengruppe Multiples 
Myeloma (DSMM)), GMMG, University Clinic, Heidelberg, and University Clinic, Ulm. Controls 
comprised 1,477 healthy German blood donors recruited between 2004 and 2007 by the Institute 
of Transfusion Medicine and Immunology, University of Mannheim, Germany. The Swedish 
replication series comprised 534 MM cases from the Swedish National Myeloma Biobank and the 
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Danish replication series comprised 332 MM cases from the University Hospital of Copenhagen. As 
controls, we analysed 2,382 Swedish blood donors and 2,229 individuals from Denmark and Skåne 
County, Sweden (the southernmost part of Sweden adjacent to Denmark). Replication genotyping 
of German and Scandinavian samples was performed using competitive allele-specific PCR KASPar 
chemistry (LGC, Hertfordshire, UK). Call rates for SNP genotypes were >95% in each of the 
replication series. To ensure the quality of genotyping in all assays, at least two negative controls 
and duplicate samples (showing a concordance of >99%) were genotyped at each centre. The 
fidelity of imputation was assessed by directly sequencing a set of 147 randomly selected samples 
from the UK OncoArray case series. Imputation was found to be robust; concordance was >90% 
(Supplementary Table 13). Genotyping and sequencing primers are detailed in Supplementary 
Table 14 and 15, respectively. 
 
Meta-analysis 
Meta-analyses were performed using the fixed-effects inverse-variance method using META v1.6 
51. Cochran's Q-statistic to test for heterogeneity and the I2 statistic to quantify the proportion of 
the total variation due to heterogeneity was calculated. Using the meta-analysis summary 
statistics and LD correlations from a reference panel of the 1000 Genomes Project combined with 
UK10K, we implemented Genome-wide Complex Trait Analysis52 to perform conditional 
association analysis. Association statistics were calculated for all SNPs conditioning on the top SNP 
in each loci showing genome-wide significance. This was carried out step-wise. 
 
For borderline associations, the Bayesian false-discovery probability (BFDP)10 was calculated based 
on a plausible OR of 1.2 and a prior probability of association of 0.0001. For both promising 
associations, the BFDP was <10%. 
 
Fluorescence in situ hybridization  
Fluorescence in situ hybridization (FISH) and ploidy classification of UK and German samples were 
performed as previously described53,54. Logistic regression in case-only analyses was used to assess 
the relationship between SNP genotype and IgH translocations or tumour ploidy.  
 
eQTL analysis 
eQTL analyses were performed using CD138-purified plasma cells from 183 UK MyIX trial patients 
and 658 German GMMG patients32. Briefly, German and UK data were pre-processed separately, 
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followed by analysis using a Bayesian approach to probabilistic estimation of expression residuals 
to infer broad variance components, accounting for hidden determinants influencing global 
expression. The association between genotype of SNPs and expression of genes within 1 Mb either 
side of each MM risk locus was evaluated based on the significance of linear regression 
coefficients. We pooled data from each study under a fixed-effects model. 
 
The relationship between SNP genotype and gene expression we carried out using Summary-data-
based Mendelian Randomization (SMR) analysis as per Zhu et al20. Briefly, if bxy is the effect size of 
x (gene expression) on y (slope of y regressed on the genetic value of x), bzx is the effect of z on x, 
and bzy be the effect of z on y, bxy (bzy/bzx) is the effect of x on y. To distinguish pleiotropy from 
linkage where the top associated cis-eQTL is in LD with two causal variants, one affecting gene 
expression the other affecting trait we tested for heterogeneity in dependent instruments (HEIDI), 
using multiple SNPs in each cis-eQTL region. Under the hypothesis of pleiotropy bxy values for SNPs 
in LD with the causal variant should be identical. For each probe that passed significance threshold 
for the SMR test, we tested the heterogeneity in the bxy values estimated for multiple SNPs in the 
cis-eQTL region using HEIDI. 
 
GWAS summary statistics files were generated from the meta-analysis. We set a threshold for the 
SMR test of PSMR < 1 × 10
-3 corresponding to a Bonferroni correction for 45 tests, i.e. 45 probes 
which demonstrated an association in the SMR test. For all genes passing this threshold we 
generated plots of the eQTL and GWAS associations at the locus, as well as plots of GWAS and 
eQTL effect sizes (i.e. input for the HEIDI heterogeneity test). HEIDI test P-values < 0.05 were 
considered as reflective of heterogeneity. This threshold is, however, conservative for gene 
discovery because it retains fewer genes than when correcting for multiple testing. SMR plots for 
significant eQTLs are shown in Supplementary Fig. 9 and 10 and a summary of results are shown 
in Supplementary Table 16.  
 
Promoter capture Hi-C 
To map risk SNPs to interactions involving promoter contacts and identify genes involved in MM 
susceptibility, we analysed publicly accessible promoter capture Hi-C (CHi-C) data on the naïve B-
cells downloaded from Blueprint Epigenome Project. Additionally, we also analysed promotor CHi-
C data we have previously generated for the MM cell line KMS1112. Interactions were called using 
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the CHiCAGO pipeline to obtain a unique list of reproducible contacts55 and those with a 
−log(weighted P) ≥5 were considered significant.  
 
Chromatin state annotation 
Variant sets (i.e. sentinel risk SNP and correlated SNPs, r2>0.8) were annotated for putative 
functional effect based upon histone mark ChIP-seq data for H3K27ac, H3K4Me1, H3K27Me3 , 
H3K9Me3, H3K36Me3 and H3K27Me3 from KMS11 cell lines, generated in-house, and naïve B-
cells from Blueprint Epigenome Project56. We used ChromHMM to infer chromatin states by 
integrating information on these histone modifications, training the model on three MM cell lines; 
KMS11, MM1S and JJN3. Genome-wide signal tracks were binarized (including input controls for 
ChIP-seq data), and a set of learned models were generated using ChromHMM software57. A 12-
state model was suitable for interpretation and biological meaning was assigned to the states 
based on chromatin marks use putative rules as previously described (Supplementary Fig. 11).  
 
TF and histone mark enrichment analysis 
To examine enrichment in specific TF binding across risk loci, we adapted the method of Cowper-
Sal lari et al.58. Briefly, for each risk locus, a region of strong LD (defined as r2>0.8 and D′>0.8) was 
determined, and these SNPs were considered the associated variant set (AVS). Publically available 
data on TF ChIP-seq uniform peak data were obtained from ENCODE for the GM12878 cell line, 
including data for 82 TF and 11 histone marks59. In addition, ChIP-seq peak data for 6 histone 
marks from KMS11 cell line was generated in-house and naïve B-cell ChIP-seq data was 
downloaded from Blueprint Epigenome Project56. For each mark, the overlap of the SNPs in the 
AVS and the binding sites was assessed to generate a mapping tally. A null distribution was 
produced by randomly selecting SNPs with the same characteristics as the risk-associated SNPs, 
and the null mapping tally calculated. This process was repeated 10,000 times, and P-values 
calculated as the proportion of permutations where null mapping tally was greater or equal to the 
AVS mapping tally. An enrichment score was calculated by normalizing the tallies to the median of 
the null distribution. Thus, the enrichment score is the number of standard deviations of the AVS 
mapping tally from the median of the null distribution tallies. Enrichment plots are shown in 
Supplementary Fig. 4 and 5. 
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Functional annotation 
For the integrated functional annotation of risk loci, variant sets (i.e. all SNPs in LD r2 > 0.8 with the 
sentinel SNP) were annotated with: (i) presence of a Hi-C contact linking to a gene promoter, (ii) 
presence of an association from SMR analysis, (iii) presence of a regulatory ChromHMM state, (iv) 
evidence of transcription factor binding, (v) presence of a nonsynonymous coding change. 
Candidate causal genes were then assigned to MM risk loci using the target genes implicated in 
annotation tracks (i), (ii), (iiii) and (iv). If the data supported multiple gene candidates, the gene 
with the highest number of individual functional data points was considered as the candidate. 
Where multiple genes have the same number of data points, all genes are listed. Direct non-
synonymous coding variants were allocated additional weighting. Competing mechanisms for the 
same gene (e.g. both coding and promoter variants) were permitted. 
 
Heritability analysis 
We used LDAK to estimate the polygenic variance (i.e. heritability) ascribable to all genotyped and 
imputed GWAS SNPs from summary statistic data. SNP specific expected heritability, adjusted for 
LD, MAF and genotype certainty was calculated from the UK10K and 1000 Genomes data.  
Samples were excluded with a call rate <0.99 or if individuals were closely related or of divergent 
ancestry from CEU. Individual SNPs were excluded if they showed deviation from HWE with P < 
1 × 10−5, an individual SNP genotype yield <95%, MAF <1%, SNP imputation score <0.99 and the 
absence of the SNP in the GWAS summary statistic data. This resulted in a total 1,254,459 SNPs 
which were used to estimate the heritability of MM. 
 
To estimate the sample size required for a given proportion of the GWAS heritability we 
implemented a likelihood-based approach to model the effect-size distribution15, using association 
statistics from the MM meta-analysis, and LD information from individuals of European ancestry in 
the 1000 Genomes Project Phase 3. LD values were based on an r2 threshold of 0.1 and a window 
size of 1 MB. The goodness of fit of the observed distribution of P-values against the expected 
from a two-component model (single normal distribution) and a three-component model (mixture 
of two normal distributions) were assessed15, and a better fit was observed for the latter model 
(Supplementary Figure 4). The percentage of GWAS heritability explained for a projected sample 
size was determined using this model and is based on power calculations for the discovery of 
genome-wide significant SNPs. The genetic variance explained was calculated as the proportion of 
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total GWAS heritability explained by SNPs reaching genome-wide significance at a given sample 
size. The 95% confidence intervals were determined using 10,000 simulations. 
 
Polygenic risk scores for familial MM (n=38) from 25 families were compared with sporadic MM 
(n=1,530) and population-based controls (n=10,171); first as a simple sum of risk alleles and 
secondly as sum of risk alleles weighted by their log-transformed odds ratios. Family member 
scores were averaged. A one-sided Student’s t-test was used to assess difference between groups. 
The genetic data has been previously described5,60 with the familial MM cases having been 
identified by linkages of Swedish registry information. 
 
Data availability 
SNP genotyping data that support the findings of this study have been deposited in Gene 
Expression Omnibus with accession codes GSE21349, GSE19784, GSE24080, GSE2658 and 
GSE15695; in the European Genome-phenome Archive (EGA) with accession code 
EGAS00000000001; in the European Bioinformatics Institute (Part of the European Molecular 
Biology Laboratory) (EMBL-EBI) with accession code E-MTAB-362 and E-TABM-1138; and in the 
database of Genotypes and Phenotypes (dbGaP) with accession code phs000207.v1.p1. Expression 
data that support the findings of this study have been deposited in GEO with accession codes 
GSE21349, GSE2658, GSE31161 and EMBL-EBI with accession code E-MTAB-2299. The remaining 
data are contained within the paper and Supplementary Files or available from the author upon 
request. KMS11 Hi-C data used in this manuscript are deposited in EGA under accession number 
EGAS00001002614. The accession number for the KMS11 ChIP-seq data reported in this paper is 
EGA: S00001002414. Naïve B-cell HiC data used in this work is publically available from Blueprint 
Blueprint Epigenome Project [https://osf.io/u8tzp/]. ChIP-seq data for H3K27ac, H3K4Me1, 
H3K27Me3, H3K9Me3, H3K36Me3 and H3K27Me3 from naïve B-cells is publically available and 
was obtained from Blueprint Epigenome Project [http://www.blueprint-epigenome.eu/].  
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 OncoArray Previous data Replication Combined meta 
SNP Locus Chr. Pos. (b37) 
Risk 
Allele RAF OR P OR Pmeta OR  Pmeta OR Pmeta I
2 
rs7577599 2p23.3 2 25613146 T 0.81 1.22 2.63×10-3 1.24 1.24×10-16 - - 1.23 1.29×10-18 0 
               rs4325816 2q31.1 2 174808899 T 0.77 1.16 1.23×10-2 1.11 1.30×10-5 1.16 3.00×10-3 1.12 7.37×10-9 9 
               rs6599192 3p22.1 3 41992408 G 0.16 1.24 1.35×10-3 1.26 8.75×10-18 - - 1.26 4.96×10-20 0 
               rs10936600 3q26.2 3 169514585 A 0.75 1.18 5.12×10-3 1.20 5.94×10-15 - - 1.20 1.20×10-16 0 
               rs1423269 5q15 5 95255724 A 0.75 1.09 0.125 1.17 1.57×10-11 - - 1.16 8.30×10-12 23 
               rs6595443 5q23.2 5 122743325 T 0.43 1.14 9.87×10-3 1.10 4.69×10-6 1.10 0.022 1.11 1.20×10-8 0 
               rs34229995 6p22.3 6 15244018 G 0.02 1.05 0.781 1.40 1.76×10-8 - - 1.36 5.60×10-8 0 
               rs3132535 6p21.3 6 31116526 A 0.29 1.26 2.67×10-5 1.20 2.97×10-17 - - 1.21 6.00×10-21 0 
               rs9372120 6q21 6 106667535 G 0.21 1.18 7.74×10-3 1.20 8.72×10-14 - - 1.19 2.40×10-15 0 
               rs4487645 7p15.3 7 21938240 C 0.65 1.23 1.06×10-4 1.24 5.30×10-25 - - 1.24 2.80×10-28 0 
               rs17507636 7q22.3 7 106291118 C 0.74 1.12 5.71×10-2 1.12 5.54×10-7 1.10 0.036 1.12 9.20×10-9 50 
               rs58618031 7q31.33 7 124583896 T 0.72 1.17 7.61×10-3 1.11 4.70×10-6 1.10 0.061 1.12 2.73×10-8 0 
Table 1 (continued on following page) 
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 OncoArray Previous data Replication Combined meta 
SNP Locus Chr. Pos. (b37) 
Risk 
Allele RAF OR P OR Pmeta OR  Pmeta OR Pmeta I
2 
rs7781265 7q36.1 7 150950940 A 0.12 1.33 3.23×10-4 1.20 1.82×10-7 - - 1.22 4.82×10-10 49 
               rs1948915 8q24.21 8 128222421 C 0.32 1.19 1.68×10-3 1.14 3.14×10-10 - - 1.15 2.53×10-12 26 
               rs2811710 9p21.3 9 21991923 C 0.63 1.13 1.76×10-2 1.14 6.50×10-10 - - 1.14 3.64×10-11 0 
               rs2790457 10p12.1 10 28856819 G 0.73 1.09 0.124 1.12 8.44×10-7 - - 1.11 2.66×10-6 0 
               rs1333894
6 16p11.2 16 30700858 C 0.26 1.17 7.90×10-3 1.12 2.22×10-7 1.26 2.5×10-7 1.15 1.02×10-13 26 
               rs7193541 16q23.1 16 74664743 T 0.58 1.14 9.01×10-3 1.12 1.14×10-8 - - 1.12 3.68×10-10 34 
               rs34562254 17p11.2 17 16842991 A 0.10 1.32 7.63×10-4 1.30 3.63×10-17 - - 1.30 1.18×10-19 29 
               rs1108602
9 
19p13.1
1 19 16438661 T 0.24 1.26 1.02×10-4 1.12 1.69×10-6 1.15 5.00×10-3 1.14 6.79×10-11 42 
               
rs6066835 
20q13.1
3 20 47355009 C 0.08 1.13 0.162 1.24 1.16×10-9 - - 1.23 6.58×10-10 38 
               rs138747 22q13.1 22 35700488 A 0.66 - - 1.21 2.58×10-8 - - 1.21 2.58×10-8 0 
               rs139402 22q13.1 22 39546145 C 0.44 1.11 4.146×10-2 1.23 4.98×10-26 - - 1.22 3.84×10-26 56 
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Table 1 
 
        Functional evidence 
SNP  Locus bp(b37)  Genes in LD block Coding variant 
Promoter 
variant 
Promoter/ enhancer 
chromatin states 
TF binding1 
Hi-C contact(s) in 
KMS11 cells 
Hi-C contact(s) in 
naïve B-cells 
eQTL 
Functional 
study 
Candidate 
causal 
gene(s) 
Candidate disease 
mechanism 
rs7577599 2p23.3 25613146 DTNB 
          
                            
rs4325816 2q31.1 174808899 SP3 
 
SP3 
active promoter, 
transcribed enhancer 
weakly acetylated, 
intermediate enhancer 
BATF, CTCF, 
MAZ, NFIC,  
RAD21, YY1 
    
SP3 
Chromatin 
remodelling 
                            
rs6599192 3p22.1 41992408 ULK4 
          
                            
rs10936600 3q26.2 169514585 ACTRT3 MYNN LRRC34 LRRC34 
 
active promoter, distal 
promoter 
ATF2, EBF1, 
MAZ, MXI1, 
POL2RA, SIN3A,  
STAT5A, TAF1, 
TBLR1XR1 +21 
GPR160, SEC62-
AS1 
GPR160, LRRC31, 
MYNN, PDCD10, 
SERPINI1, SEC62, 
SAMD7, SEC62-
AS1, SKIL, PHC3, 
PDCD10 
  
LRRC34 
 
                            
rs1423269 5q15 95255724 ELL2 ELL2 
 
intermediate enhancer, 
active enhancer, distal 
promoter 
ATF2, BCLAF1, 
EBF1, IKZF1, 
MAZ, MEF2C, 
MXI1, SPI1, 
STAT5A, 
TBLR1XR1 +23 
VPS13C 
   
ELL2 B-cell development 
                            
rs6595443 5q23.2 122743325 CEP120 CEP120   
transcribed enhancer 
weakly acetylated 
SPI1 SNX2,    SNX24 SNX2,    SNX24 CEP120   CEP120 
cell cycle/ genomic 
stability 
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        Functional evidence 
SNP  Locus bp(b37)  Genes in LD block Coding variant 
Promoter 
variant 
Promoter/ enhancer 
chromatin states 
TF binding1 
Hi-C contact(s) in 
KMS11 cells 
Hi-C contact(s) in 
naïve B-cells 
eQTL 
Functional 
study 
Candidate 
causal 
gene(s) 
Candidate disease 
mechanism 
rs34229995 6p22.3 15244018 JARID2 
  
intermediate enhancer, 
active promoter, distal 
promoter 
FOXM1, IKZF1, 
MEF2A, NFIC, 
RELA, RUNX3, 
SPI1, YY1, 
ZNF143 
      
                            
rs3132535 6p21.3 31116526 PSORS1C1 CCHCR1 
          
                            
rs9372120 6q21 106667535 ATG5 
  
intermediate enhancer, 
active enhancer  
PREP PRDM1, PREP 
  
PRDM1 B-cell development 
                            
rs4487645 7p15.3 21938240 DNAH11 CDCA7L 
   
IRF4,  MYC, 
POLR2A, 
POU2F2, 
RUNX3,  SPI1, 
TAF1, WRNIP1 
   
CDCA7L CDCA7L apoptosis/autophagy 
                            
rs17507636 7q22.3 106291118 CCDC71L 
          
                            
rs58618031 7q31.33 124583896 POT1 
  
distal promoter, active 
enhancer, intermediate 
enhancer 
NFIC 
 
ASB15, IQUB, 
WASL    
cell cycle/ genomic 
stability 
                            
rs7781265 7q36.1 150950940 
ABCF2 CHPF2 
SMARCD3 
  ABCF2, CHPF2 
active promoter, poised 
promoter 
EBF1, EZH2, 
POLR2A, SIN3A, 
TAF1, YY1 
ASIC3,  ABCF2, 
ATG9B 
      ABCF2 chromatin remodelling 
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        Functional evidence 
SNP  Locus bp(b37)  Genes in LD block Coding variant 
Promoter 
variant 
Promoter/ enhancer 
chromatin states TF binding1 
Hi-C contact(s) in 
KMS11 cells 
Hi-C contact(s) in 
naïve B-cells eQTL 
Functional 
study 
Candidate 
causal 
gene(s) 
Candidate disease 
mechanism 
rs1948915 8q24.21 128222421 
    
ATF2, BCLAF1, 
EBF1, MAZ, 
MXI1, POL2RA, 
SIN3A, SPI1, 
STAT5A +18 
 
CASC11, MYC 
  
MYC apoptosis/ autophagy 
                            
rs2811710 9p21.3 21991923 
CDKN2A, MTAP, 
CDKN2B-AS1 
CDKN2A 
CDKN2A, 
CDKN2B-AS1 
active promoter 
 
MTAP MTAP 
  
CDKN2A, 
MTAP 
cell cycle/ genomic 
stability 
                            
rs2790457 10p12.1 28856819 WAC 
  
intermediate enhancer CTCF LYZL1 MASTL, YME1L1 WAC 
 
WAC apoptosis/ autophagy 
                            
rs13338946 16p11.2 30700858 
PRR14      FBRS      
SRCAP 
PRR14 FBRS 
active promoter, distal 
promoter 
EBF1, MAZ, 
MXI1, POL2RA, 
SIN3A, SPI1, 
TAF1 +11 
DCTPP1, DOC2A, 
FBXL19, GDPD3, 
ITGAL, MYLPF, 
PPP4C, SEPHS2, 
SEPT1, TBC1D10B, 
ZNF48, ZNF771 
FBRS, PRR14, 
DCTPP1, MYLPF, 
TBC1D10B, SEPHS2 
  
PRR14 apoptosis/ autophagy 
                            
rs7193541 16q23.1 74664743 RFWD3   GLG1 RFWD3 RFWD3 active promoter PML, TBP GLG1, NPIPL2 
GLG1, HSPE1P, 
CFDP1, PSMD7, 
RFWD3, 
GABARAPL2 
    RFWD3   
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        Functional evidence 
SNP  Locus bp(b37)  Genes in LD block Coding variant 
Promoter 
variant 
Promoter/ enhancer 
chromatin states 
TF binding1 
Hi-C contact(s) in 
KMS11 cells 
Hi-C contact(s) in 
naïve B-cells 
eQTL 
Functional 
study 
Candidate 
causal 
gene(s) 
Candidate disease 
mechanism 
rs34562254 17p11.2 16842991 TNFRSF13B TNFRSF13B 
 
intermediate enhancer, 
distal promoter, active 
enhancer 
CTCF, POL2RA, 
STAT5A     
TNFRSF13B B-cell development 
                            
rs11086029 19p13.11 16438661 KLF2 KLF2 KLF2 poised promoter 
CTCF, EGR1, 
IKZF1, NFYB, 
POLR2A, RFX5, 
SIN3A, SPI1 
    
KLF2 apoptosis/ autophagy 
                            
rs6066835 20q13.13 47355009 PREX1 
  
poised promoter 
ATF2, EBF1, 
IKZF1, MEF2C, 
POL2RA, SPI1, 
TBLR1XR1 +9 
 
ARFGEF2 
    
                            
rs138747 22q13.1 35700488 HMGXB4 TOM1 HMGXB4 
TOM1, 
HMGXB4 
active promoter, 
transcribed enhancer 
weakly acetylated, 
intermediate enhancer, 
distal promoter, active 
enhancer, transcribed weak 
enhancer weakly acetylated  
BCLAF1, EBF1, 
MAZ, POL2RA, 
STAT5A +46 
CRYBB1, HMOX1, 
APOL3, TOM1, 
LARGE, HMGXB4 
FBXO7, HMGXB4, 
RASD2, MB     
                            
rs139402 22q13.1 39546145 CBX7   CBX7 
distal promoter, 
intermediate enhancer, 
active promoter, poised 
promoter 
BCLAF1, CHD2, 
CTCF, EBF1, 
MAZ, NFYB, 
POLR2A, RELA, 
RFX5, TBP, 
TAF1, ZNF143 
  
APOBEC3B-AS1, 
RPL3 
    CBX7 chromatin remodelling 
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Figure 2. 
FIGURE AND TABLE LEGENDS 
Figure 1: GWAS study design  
Details of the new and existing GWAS samples, including recruitment centres or trials and 
quality control, are provided in Supplementary Tables 1 and 2. Trials or centres from which 
replication samples were recruited are detailed in Supplementary Table 3. Ca., cases; Co., 
controls; eQTL, expression quantitative trait loci; SNP, single nucleotide polymorphism; LD, 
linkage disequilibrium. 
Figure 2: Regional plots of the six new risk loci 
Regional plots of loci (a) 2q31.1, (b) 5q23.2, (c) 7q22.3, (d) 7q31.33, (e) 16p11.2 and (f) 
19p13.11. Plots show results of the meta-analysis for both genotyped (triangles) and 
imputed (circles) single nucleotide polymorphisms (SNPs), and recombination rates. 
−log10(P) (y axes) of the SNPs are shown according to their chromosomal positions (x axes). 
The sentinel SNP in each combined analysis is shown as a large circle or triangle and is 
labelled by its rsID. The colour intensity of each symbol reflects the extent of LD with the top 
SNP, white (r2 = 0) through to dark red (r2 = 1.0). Genetic recombination rates, estimated 
using 1000 Genomes Project samples, are shown with a light blue line. Physical positions are 
based on NCBI build 37 of the human genome. Also shown are the relative positions of 
genes and transcripts mapping to the region of association. Genes have been redrawn to 
show their relative positions; therefore maps are not to physical scale. The middle track 
represents the chromatin-state segmentation track (ChromHMM) for KMS11. 
Table 1: Summary of genotyping results for all 23 risk SNPs  
New loci discovered through this study are emboldened. 
RAF, risk allele frequency; Ptrend, P-value for trend, via logistic regression; Pmeta, P-value for 
fixed effects meta-analysis; I2, heterogeneity index (0–100). RAF are based on the UK cohort 
control series, with the exception of rs138747, which is sourced from the 1000 Genomes 
Project61.  
 
Table 2: Summary of functional annotation of the 23 risk loci 
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Newly identified risk loci are emboldened. 1 Where > 10 TF were implicated at a locus, only 
those that overlap with TF which demonstrated enrichment in GM12878 are shown here. A 
full list of TFs localising to loci are detailed in Supplementary Table 17. 
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SUPPLEMENTARY INFORMATION 
 
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to 
multiple myeloma 
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Trial/Recruitment Centre Pre-QC
Sex 
discrepancy 
Call rate 
fail
Heterozygosity 
rate
Related 
Individuals
Non-European 
Ancestary
Post-QC
Cases UK MRC MyIX, UK MRC MyXI 2,329 10 1 NA 2 34 2,282
Controls 1958 Birth Cohort, National Blood Service 5,199 0 0 NA 2 0 5,197
Cases
Swedish National Myeloma Biobank
Norwegian Biobank for Myeloma
1,714
Controls TWINGENE 10,391
Cases GMMG-HD3, GMMG-HD4, GMMG-HD5 1,512 1 0 NA 0 3 1,508
Controls Heinz Nixdorf Recall 2,107 0 0 NA 0 0 2,107
Cases
HOVON65/GMMG-HD4, 
HOVON95/EMN02, HOVON87/NMSG18
608 0 2 7 0 44 555
Controls B-PROOF 2,669 0 0 0 0 0 2,669
Cases
Total Therapy II, Total Therapy III, 
Total Therapy 3B, Total Therapy 4
1,076 0 0 9 1 286 780
Controls  Cancer Genetic Markers of Susceptibility 2,234 0 4 2 0 369 1,857
Cases Icelandic Cancer Registry 480
Controls deCODE 212,164
Cases UK MRC MyXI 931 6 1 5 3 44 878
Controls PRACTICAL, BCAC 7,519 8 1 7 68 364 7,083
OncoArray
UK
Sweden/Norway
Germany
Netherlands
USA
Iceland
Supplementary Table 1: Details of the quality control filters applied to each GWAS. Samples were excluded due to call rate (<95% or failed genotyping), 
ancestry (principle components analysis or other samples reported to be not of white, European descent), relatedness (any individuals found to be 
duplicated or related within or between data sets through IBS) or sex discrepancy. Dutch, German, UK, USA, Sweden/Norway and Iceland: These studies 
have been previously reported in their entirety with comprehensive details on QC1-4. MyIX, Myeloma IX; MyXI, Myeloma XI; B-PROOF, B-vitamins for the 
prevention of osteoporotic fractures; UKGPCS, UK Genetic Prostate Cancer Study; BCAC, Breast Cancer Association Consortium. 
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Pre-QC Call rate fail HWE fail MAF < 0.01 Post-QC Imputed (filtered)
UK 409,429 997 7 3 408,422 8,517,071
Sweden/Norway 7,182,761
Germany 401,405 113 0 1 401,291 8,282,831
Netherlands 646,124 6,523 18,104 0 621,497 8,628,799
USA 296,998 4 171 9,151 287,672 8,085,846
Iceland 10,291,845
OncoArray 459,068 6,851 12 73,239 378,966 8,309,850
Supplementary Table 2: Details of the quality control filters applied to each GWAS. For the OncoArray genotyped SNPs with a call rate <95% were 
excluded as were those with a MAF <0.01 or showing significant deviation from Hardy-Weinberg equilibrium (i.e. P < 10-5). Imputed SNPs with 
information score <0.8 and MAF <0.01 were excluded. Dutch, German, UK, USA, Sweden/Norway and Iceland: These studies have been previously 
reported in their entirety with comprehensive details on QC1-4. 
Went et al  
Supplementary Information 41 
 
 
  
Samples Trial/Recruitment Centre
Cases 911 German Myeloma Study Group
Controls 1,477
Institute of Transfusion Medicine and Immunology, 
University of Mannheim, Germany
Cases 534 Swedish National Myeloma Biobank
Controls 2,382 Swedish blood donors
Cases 332 University Hospital of Copenhagen
Controls 2,229 Individuals from Denmark and Skåne County
Supplementary Table 3: Details of the replication sample recruitment. 
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(Table continued on following page)  
  
SNP Chr. Pos. (b37) Risk Allele Cases RAF Controls RAF OR P- value Cases RAF Controls RAF OR P- value Cases RAF Controls RAF OR P- value
rs4325816 2 174808899 T 0.79 0.76 1.16 0.012 0.78 0.76 1.10 0.24 0.79 0.75 1.21 0.002
rs6595443 5 122743325 T 0.47 0.44 1.14 0.010 0.44 0.43 1.04 0.52 0.47 0.45 1.10 0.087
rs17507636 7 106291118 C 0.77 0.75 1.12 0.057 0.76 0.73 1.16 0.04 0.75 0.71 1.14 0.028
rs58618031 7 124583896 T 0.76 0.73 1.17 0.008 0.73 0.72 1.08 0.30 0.75 0.72 1.16 0.012
rs13338946 16 30700858 C 0.28 0.25 1.17 0.008 0.26 0.25 1.09 0.24 0.29 0.27 1.11 0.078
rs11086029 19 16438661 T 0.29 0.25 1.26 1.01×10-4 0.25 0.24 1.04 0.65 0.23 0.22 1.05 0.466
rs1050976 6 408079 T 0.53 0.51 1.09 0.080 0.50 0.45 1.21 3.7×10-3 0.47 0.46 1.03 0.525
rs11629542 15 90098754 G 0.58 0.55 1.16 0.004 0.58 0.55 1.12 0.10 0.56 0.56 1.03 0.635
rs17501560 7 81415783 A 0.85 0.82 1.24 0.001 0.82 0.81 1.03 0.72 0.82 0.80 1.12 0.098
OncoArray Netherlands German
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(Table continued on following page)  
  
SNP Chr. Pos. (b37) Risk Allele Cases RAF Controls RAF OR P- value Cases RAF Controls RAF OR P- value Cases RAF Controls RAF OR P- value
rs4325816 2 174808899 T 0.78 0.77 1.07 0.141 0.79 0.77 1.12 0.006 0.80 0.78 1.18 0.026
rs6595443 5 122743325 T 0.17 0.16 1.15 0.010 0.45 0.43 1.06 0.080 0.47 0.41 1.27 1.13×10-4
rs17507636 7 106291118 C 0.78 0.76 1.09 0.044 0.76 0.74 1.08 0.048 0.79 0.74 1.30 2.03×10-4
rs58618031 7 124583896 T 0.48 0.50 1.09 0.039 0.74 0.72 1.10 0.019 0.76 0.72 1.20 0.008
rs13338946 16 30700858 C 0.29 0.27 1.12 0.008 0.28 0.26 1.14 0.001 0.27 0.26 1.08 0.232
rs11086029 19 16438661 T 0.24 0.23 1.08 0.067 0.27 0.24 1.13 0.002 0.28 0.22 1.38 6.4 ×10-6
rs1050976 6 408079 T 0.47 0.45 1.06 0.119 0.56 0.53 1.12 0.001 0.53 0.51 1.10 0.109
rs11629542 15 90098754 G 0.56 0.56 1.05 0.171 0.57 0.54 1.13 0.001 0.58 0.54 1.18 0.006
rs17501560 7 81415783 A 0.83 0.81 1.15 0.004 0.83 0.81 1.11 0.025 0.81 0.80 1.04 0.624
Sweden UK USA
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Iceland
SNP Chr. Pos. (b37) Risk Allele Cases RAF Controls RAF OR P- value OR P- value I 2 OR P- value I 2
rs4325816 2 174808899 T - - 0.94 0.50 1.12 6.44×10-7 21 1.12 7.37×10-9 9
rs6595443 5 122743325 T - - 1.07 0.39 1.11 1.76×10-7 25 1.11 1.20×10-8 0
rs17507636 7 106291118 C - - 1.06 0.49 1.12 8.52×10-8 1 1.12 9.20×10-9 50
rs58618031 7 124583896 T - - 1.01 0.87 1.11 1.66×10-7 0 1.12 2.73×10-8 0
rs13338946 16 30700858 C - - 1.19 0.03 1.13 7.14×10-9 0 1.15 1.02×10-13 26
rs11086029 19 16438661 T - - 1.08 0.38 1.14 4.17×10-9 60 1.14 6.79×10-11 42
rs1050976 6 408079 T - - 1.15 0.07 1.10 3.74×10-7 0 1.10 5.93×10-8 0
rs11629542 15 90098754 G - - 1.09 0.23 1.10 2.37×10-7 0 1.08 2.75×10-6 40
rs17501560 7 81415783 A - - 1.19 0.05 1.13 3.85×10-7 0 1.12 9.90×10-8 0
Meta GWAS + REPMeta GWAS
Supplementary Table 4: Summary statistics for novel variants showing an association with multiple myeloma risk in the GWAS meta-analysis at P < 
1.0 × 10-6. These were taken forward for replication and those which showed association at P < 5× 10-8 were considered genome-wide significant. Odds 
ratios derived with respect to the risk allele. Cases RAF, risk allele frequency in discovery cases. Controls RAF, risk allele frequency in discovery controls. 
Shown are discovery association P values for individual studies. MetaGWAS shows a meta-analysis of previously published GWAS including new discovery 
OncoArray dataset. MetaGWAS+REP represents a meta-analysis of previously published GWAS, new discovery OncoArray dataset and replication series. 
Heterogeneity index, I2 (0-100), quantifies the proportion of the total variation due to heterogeneity. 
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  Supplementary Table 5: Replication of top association signals. Showing SNPs which were taken forward for replication genotyping. Cases RAF, risk 
allele frequency of replication cases; Control RAF, risk allele frequency of replication controls. P values are shown for each replication series (logistic 
regression). rs17507636 had been previously replicated in the German cohort, with association values4; cases RAF: 0.760, controls RAF: 0.735, OR: 
1.15, P value: 0.06. A meta-analysis of this with discovery cohorts and replication series was performed using R version 3.3.1 (R Development Core 
Team, Vienna, Austria). 
SNP Chr. Pos. (b37)
Risk 
Allele
Cases 
RAF
Controls 
RAF OR P- value
Cases 
RAF
Controls 
RAF OR P- value
Cases 
RAF
Controls 
RAF OR P- value
rs4325816 2 174808899 T 0.79 0.76 1.19 0.014 0.78 0.77 1.06 0.461 0.83 0.79 1.25 0.037
rs6595443 5 122743325 T 0.47 0.45 1.08 0.202 0.45 0.42 1.15 0.038 0.44 0.43 1.04 0.639
rs17507636 7 106291118 C - - - - 0.79 0.76 1.19 0.036 0.74 0.75 0.93 0.485
rs58618031 7 124583896 T - - - - 0.75 0.72 1.18 0.032 0.72 0.71 1.03 0.761
rs13338946 16 30700858 C 0.32 0.28 1.24 0.001 0.29 0.27 1.13 0.112 0.37 0.28 1.51 9.0 ×10-6
rs11086029 19 16438661 T 0.23 0.21 1.18 0.022 0.24 0.22 1.12 0.149 0.26 0.24 1.11 0.293
rs1050976 6 408079 T 0.49 0.47 1.07 0.268 0.47 0.45 1.10 0.188 0.48 0.46 1.08 0.371
rs11629542 15 90098754 G 0.44 0.46 0.92 0.205 0.54 0.54 1.01 0.910 0.57 0.54 1.16 0.091
rs17501560 7 81415783 A 0.81 0.81 1.00 0.954 0.83 0.80 1.22 0.016 0.82 0.81 1.08 0.461
German Replication Swedish Replication Danish Replication
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RSID Beta  P- value Beta P- value Beta P- value Beta  P- value OR P- value I
2
P HET
rs34229995 -0.43 0.15 -0.08 0.69 -0.23 0.50 -0.05 0.79 0.87 0.69 - 1.10 0.23 0 0.73
rs9372120 0.16 0.20 -0.11 0.22 0.02 0.87 -0.01 0.85 0.99 0.90 - 1.08 0.84 6 0.36
rs7781265 -0.06 0.69 0.02 0.84 0.15 0.28 -0.11 0.22 0.98 0.87 - 1.10 0.72 0 0.44
rs1948915 0.02 0.86 0.05 0.53 0.07 0.49 0.04 0.58 1.04 0.96 - 1.13 0.30 0 0.99
rs2811710 0.13 0.24 0.03 0.74 -0.02 0.83 -0.03 0.67 1.01 0.93 - 1.10 0.80 0 0.65
rs2790457 0.04 0.75 0.06 0.45 -0.02 0.83 0.12 0.08 1.07 0.98 - 1.17 0.12 0 0.73
rs7193541 0.05 0.67 0.01 0.88 0.08 0.44 0.02 0.74 1.03 0.95 - 1.12 0.44 0 0.95
rs6066835 -0.60 0.00 -0.24 0.06 0.30 0.07 0.07 0.49 0.94 0.83 - 1.07 0.36 82 0.00
rs7577599 -0.04 0.79 -0.10 0.33 0.22 0.12 0.01 0.94 1.00 0.90 - 1.12 0.96 14 0.32
rs6599192 0.12 0.37 0.01 0.93 -0.13 0.28 -0.03 0.67 0.98 0.89 - 1.08 0.73 0 0.56
rs4487645 0.09 0.46 -0.03 0.79 0.04 0.73 0.07 0.29 1.05 0.96 - 1.16 0.27 0 0.89
rs34562254 0.19 0.24 -0.07 0.51 -0.01 0.93 0.05 0.60 1.02 0.91 - 1.14 0.72 0 0.58
rs3132535 0.03 0.82 0.11 0.17 -0.12 0.25 0.03 0.61 1.03 0.95 - 1.12 0.49 0 0.39
rs1423269 0.25 0.04 0.00 0.99 0.02 0.87 0.10 0.15 1.09 0.99 - 1.19 0.07 5 0.37
rs139402 -0.06 0.56 -0.09 0.24 -0.11 0.27 0.01 0.83 0.96 0.89 - 1.03 0.25 0 0.64
rs138747 -0.34 0.21 0.22 0.17 -0.46 0.04 -0.04 0.80 0.94 0.79 - 1.13 0.51 59 0.06
rs10936600 0.13 0.30 0.02 0.85 -0.10 0.40 -0.04 0.55 0.99 0.90 - 1.09 0.81 0 0.54
rs11086029 -0.11 0.40 0.15 0.21 -0.06 0.16 -0.10 0.41 0.96 0.88 - 1.05 0.37 27 0.25
rs13338946 0.08 0.51 0.07 0.31 0.07 0.49 -0.08 0.28 1.06 0.97 - 1.15 0.20 0 0.69
rs17507636 0.06 0.14 -0.04 0.50 0.09 0.75 -0.20 0.22 1.03 0.94 - 1.12 0.59 25 0.26
rs4325816 -0.02 0.91 0.01 0.80 -0.04 0.96 -0.01 0.56 0.97 0.89 - 1.07 0.60 0 0.99
rs58618031 0.05 0.19 0.01 0.56 -0.06 0.96 -0.16 0.48 0.97 0.89 - 1.07 0.56 0 0.53
rs6595443 0.13 0.36 0.07 0.09 0.09 0.47 -0.10 0.12 1.08 1.00 - 1.16 0.07 8 0.35
95% CIs
USA Germany OncoArray UK Meta
Supplementary Table 6: Relationship between SNP genotype and sex. Analysis based on beta values calculated from logistic regression on the 
discovery phase data sets from UK (2282 cases), Oncoarray (878 cases), German (1508 cases) and USA (780 cases) series. The meta-analysis was 
conducted using a fixed-effects model. This assumes that the underlying effect across all studies is the same. To test for potential heterogeneity, 
Cochran’s Q-statistic was calculated such that PHET >0.05 implied the presence of non-significant heterogeneity. The heterogeneity index, I
2 (0-100), 
was also measured; this quantifies the proportion of the total variation due to heterogeneity.  
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RSID Beta  P- value Beta  P- value Beta  P- value Beta  P- value OR P- value I
2
P HET
rs34229995 0.93 0.45 0.07 0.94 -1.34 0.43 0.44 0.67 1.23 0.40 - 3.79 0.71 0 0.74
rs9372120 -1.18 0.03 0.15 0.74 0.31 0.60 0.64 0.08 1.15 0.74 - 1.80 0.53 61 0.05
rs7781265 0.02 0.97 -0.41 0.43 0.45 0.53 -0.09 0.84 0.92 0.53 - 1.61 0.77 0 0.80
rs1948915 0.28 0.56 0.36 0.35 -0.22 0.68 -0.43 0.19 0.95 0.64 - 1.43 0.82 0.5 0.39
rs2811710 -0.02 0.97 -0.40 0.32 -0.01 0.98 -0.20 0.56 0.83 0.55 - 1.25 0.36 0 0.92
rs2790457 0.51 0.36 -0.24 0.57 -0.14 0.80 -0.36 0.31 0.86 0.55 - 1.33 0.50 0 0.62
rs7193541 -0.55 0.25 -0.22 0.56 -0.62 0.22 -0.02 0.94 0.77 0.53 - 1.14 0.19 0 0.69
rs6066835 -0.71 0.35 0.14 0.82 -1.45 0.08 -0.07 0.88 0.71 0.38 - 1.34 0.29 0 0.40
rs7577599 -0.50 0.46 0.22 0.63 0.87 0.21 0.13 0.75 1.19 0.71 - 1.97 0.51 0 0.56
rs6599192 -0.68 0.26 -0.20 0.63 -0.52 0.40 0.04 0.92 0.79 0.50 - 1.26 0.33 0 0.73
rs4487645 -0.68 0.19 0.33 0.56 -0.46 0.40 0.18 0.58 0.93 0.60 - 1.45 0.75 0 0.39
rs34562254 -1.00 0.16 0.35 0.45 0.35 0.62 -0.14 0.76 0.98 0.57 - 1.66 0.93 0 0.40
rs3132535 0.03 0.95 -0.28 0.40 -0.65 0.22 0.02 0.94 0.84 0.57 - 1.24 0.38 0 0.70
rs1423269 0.50 0.36 -0.54 0.16 -1.06 0.06 0.23 0.53 0.85 0.55 - 1.30 0.45 52 0.10
rs139402 -0.32 0.50 0.68 0.03 0.89 0.07 -0.30 0.32 1.22 0.85 - 1.75 0.29 63 0.04
rs138747 1.33 0.24 1.03 0.15 0.86 0.45 0.71 0.34 2.56 1.10 - 5.95 0.03 0 0.97
rs10936600 0.49 0.40 -0.48 0.22 -1.55 0.01 -0.53 0.17 0.61 1.00 - 2.47 0.03 51 0.11
rs11086029 -1.10 0.04 -0.27 0.48 -1.36 0.11 -0.17 0.61 0.64 0.41 - 0.99 0.04 15 0.32
rs13338946 -1.07 0.04 -0.30 0.41 0.25 0.65 0.50 0.14 0.95 0.64 - 1.43 0.81 59 0.06
rs17507636 0.60 0.30 0.59 0.17 0.54 0.36 0.12 0.73 1.48 0.95 - 2.31 0.09 0 0.80
rs4325816 0.08 0.90 -0.36 0.37 -0.01 0.99 -0.15 0.69 0.85 0.54 - 1.33 0.48 0 0.93
rs58618031 0.22 0.69 -0.76 0.07 -0.83 0.15 -0.16 0.67 0.68 0.44 - 1.07 0.10 0 0.39
rs6595443 0.65 0.16 -0.22 0.51 -0.43 0.38 -0.26 0.39 0.89 0.62 - 1.27 0.51 15 0.32
95% CIs
USA Germany OncoArray UK Meta
Supplementary Table 7: Relationship between SNP genotype and age at diagnosis. Analysis based on beta values calculated from linear regression on 
the discovery phase data sets from UK (2282 cases), Oncoarray (878 cases), German (1508 cases) and USA (780 cases) cohorts. The meta-analysis was 
conducted using a fixed-effects model. This assumes that the underlying effect across all studies is the same. To test for potential heterogeneity, 
Cochran’s Q-statistic was calculated such that PHET >0.05 implied the presence of non-significant heterogeneity. The heterogeneity index, I
2 (0-100), was 
also measured; this quantifies the proportion of the total variation due to heterogeneity. 
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RSID Beta P- value Beta P -value Beta P -value Beta P -value
rs2790457 0.12 0.41 -0.18 0.18 0.44 0.14 0.002 0.99
rs13338946 -0.17 0.23 0.03 0.78 0.28 0.34 -0.03 0.76
rs7193541 0.13 0.29 -0.07 0.53 -0.17 0.52 0.002 0.98
rs34562254 -0.02 0.92 -0.26 0.12 -0.40 0.29 -0.17 0.14
rs11086029 -0.14 0.33 -0.11 0.39 0.11 0.70 -0.10 0.28
rs6066835 -0.13 0.54 -0.35 0.06 0.90 0.07 -0.16 0.22
rs138747 0.42 0.13 -0.18 0.52 1.00 0.10 0.20 0.28
rs139402 0.08 0.52 -0.07 0.56 -0.25 0.33 -0.02 0.78
rs4325816 0.02 0.90 -0.08 0.58 0.15 0.62 -0.01 0.88
rs6599192 0.26 0.11 -0.10 0.47 0.23 0.48 0.07 0.48
rs10936600 -0.03 0.83 0.11 0.46 0.03 0.91 0.04 0.69
rs1423269 0.12 0.44 0.05 0.70 -0.11 0.69 0.06 0.54
rs6595443 -0.30 0.02 -0.13 0.24 -0.07 0.78 -0.19 0.02
rs34229995 0.52 0.11 -0.39 0.29 -1.15 0.26 0.05 0.83
rs3132535 0.02 0.87 0.01 0.91 -0.11 0.69 0.005 0.95
rs9372120 -0.11 0.47 0.04 0.76 0.37 0.22 0.02 0.87
rs4487645 0.28 0.05 0.05 0.67 0.76 0.01 0.21 0.02
rs17507636 -0.003 0.98 0.02 0.86 -0.20 0.54 -0.01 0.95
rs58618031 -0.03 0.84 0.16 0.20 0.02 0.95 0.07 0.41
rs7781265 0.21 0.25 -0.02 0.90 0.01 0.99 0.08 0.49
rs1948915 0.03 0.83 0.15 0.20 0.02 0.94 0.09 0.30
rs2811710 0.17 0.22 -0.02 0.89 -0.16 0.56 0.04 0.63
rs7577599 0.29 0.10 -0.03 0.86 0.04 0.91 0.10 0.34
German UK OncoArray Meta
Supplementary Tables 8: Relationship between SNP genotype and t(4;14) subtype. German cases: 142, UK cases: 170, Oncoarray cases: 33, Meta: 345. 
Case-only analysis; Beta values obtained from logistic regression. FISH and ploidy classification of UK and German samples were determined as 
previously described5,6.  
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RSID Beta P- value Beta P- value Beta P- value Beta P- value
rs2790457 -0.09 0.43 0.32 0.004 -0.06 0.82 0.10 0.19
rs13338946 -0.05 0.64 0.36 0.001 -0.24 0.34 0.11 0.12
rs7193541 0.02 0.82 -0.02 0.85 0.48 0.03 0.04 0.50
rs34562254 -0.05 0.68 -0.14 0.35 -0.46 0.15 -0.12 0.19
rs11086029 -0.04 0.74 0.12 0.27 -0.11 0.66 0.03 0.70
rs6066835 -0.13 0.41 0.17 0.30 -0.44 0.29 -0.02 0.88
rs138747 0.14 0.52 -0.42 0.06 -0.36 0.50 -0.15 0.33
rs139402 -0.17 0.07 -0.09 0.37 -0.27 0.23 -0.14 0.03
rs4325816 0.004 0.97 0.04 0.75 -0.13 0.62 0.01 0.93
rs6599192 0.13 0.27 -0.03 0.83 0.13 0.65 0.06 0.46
rs10936600 -0.14 0.22 0.01 0.94 -0.26 0.32 -0.09 0.27
rs1423269 -0.003 0.98 0.13 0.26 0.12 0.61 0.07 0.37
rs6595443 -0.04 0.71 -0.09 0.34 0.21 0.36 -0.04 0.53
rs34229995 -0.23 0.35 0.03 0.92 -0.44 0.62 -0.15 0.44
rs3132535 -0.05 0.60 0.11 0.31 0.27 0.24 0.04 0.53
rs9372120 0.09 0.43 0.19 0.10 0.10 0.68 0.14 0.08
rs4487645 0.13 0.23 -0.14 0.18 -0.06 0.80 -0.01 0.87
rs17507636 0.03 0.81 -0.13 0.25 -0.05 0.85 -0.05 0.52
rs58618031 0.02 0.83 -0.05 0.66 -0.19 0.46 -0.03 0.71
rs7781265 -0.08 0.54 -0.38 0.01 -0.30 0.34 -0.22 0.02
rs1948915 -0.20 0.05 0.08 0.42 0.60 0.01 -0.003 0.96
rs2811710 0.02 0.89 -0.12 0.26 -0.08 0.71 -0.05 0.44
rs7577599 -0.11 0.42 -0.09 0.49 0.04 0.89 -0.09 0.33
German UK OncoArray Meta
Supplementary Tables 9: Relationship between SNP genotype and t(11;14) subtype. German cases: 277, UK cases: 231, Oncoarray cases: 47, Meta: 
555. Case-only analysis; Beta values obtained from logistic regression. FISH and ploidy classification of UK and German samples were determined as 
previously described5,6.  
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RSID Beta P- value Beta P- value Beta P- value Beta P- value
rs2790457 0.28 0.37 0.34 0.31 1.06 0.07 0.41 0.05
rs13338946 0.20 0.49 -0.06 0.86 -0.24 0.68 0.05 0.82
rs7193541 -0.03 0.92 -0.08 0.80 -0.05 0.93 -0.05 0.80
rs34562254 -0.24 0.52 0.56 0.20 -0.07 0.92 0.08 0.76
rs11086029 -0.18 0.57 -0.24 0.45 0.43 0.44 -0.12 0.56
rs6066835 -0.49 0.28 -0.90 0.06 0.66 0.49 -0.54 0.09
rs138747 -0.06 0.93 -0.63 0.33 0.00 1.00 -0.29 0.49
rs139402 0.24 0.36 -0.62 0.04 -0.06 0.91 -0.13 0.48
rs4325816 0.45 0.17 0.01 0.98 0.10 0.87 0.23 0.31
rs6599192 -0.42 0.22 0.19 0.61 0.08 0.90 -0.11 0.64
rs10936600 -0.12 0.71 0.04 0.91 -0.54 0.36 -0.12 0.59
rs1423269 0.61 0.06 -0.12 0.72 1.12 0.04 0.41 0.06
rs6595443 -0.45 0.10 0.08 0.78 0.14 0.79 -0.16 0.40
rs34229995 0.38 0.59 1.67 0.08 -1.06 0.59 0.70 0.20
rs3132535 -0.09 0.75 0.15 0.63 0.13 0.81 0.03 0.88
rs9372120 -0.18 0.59 0.31 0.36 -0.95 0.10 -0.08 0.71
rs4487645 0.52 0.08 0.08 0.80 -0.24 0.67 0.24 0.24
rs17507636 0.29 0.35 0.05 0.87 -0.34 0.59 0.12 0.57
rs58618031 0.10 0.75 -0.04 0.90 -0.68 0.23 -0.06 0.77
rs7781265 0.20 0.59 -0.21 0.63 0.92 0.21 0.15 0.58
rs1948915 0.05 0.86 -0.14 0.66 0.07 0.89 -0.02 0.91
rs2811710 -0.24 0.42 0.19 0.54 0.43 0.40 0.03 0.87
rs7577599 0.34 0.36 -0.39 0.33 0.70 0.36 0.07 0.77
German UK OncoArray Meta
Supplementary Tables 10: Relationship between SNP genotype and t(14;16) subtype. German cases: 29, UK cases: 24, Oncoarray cases: 8, Meta: 61 
Case-only analysis; Beta values obtained from logistic regression. FISH and ploidy classification of UK and German samples were determined as 
previously described5,6.  
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RSID Beta P- value Beta P- value Beta P- value Beta P- value
rs2790457 0.03 0.71 0.14 0.06 - - 0.10 0.09
rs13338946 -0.04 0.59 -0.05 0.50 -0.02 0.91 -0.04 0.39
rs7193541 0.08 0.28 0.04 0.57 - - 0.06 0.25
rs34562254 0.01 0.92 0.15 0.12 0.51 0.04 0.12 0.09
rs11086029 0.11 0.22 -0.01 0.92 -0.10 0.60 0.03 0.59
rs6066835 0.06 0.60 0.37 0.001 -0.40 0.21 0.20 0.01
rs138747 -0.32 0.04 -0.05 0.74 -0.28 0.49 -0.19 0.08
rs139402 0.07 0.33 0.18 0.01 0.22 0.19 0.14 0.003
rs4325816 -0.05 0.61 -0.06 0.43 - - -0.06 0.35
rs6599192 -0.15 0.13 -0.05 0.55 - - -0.09 0.15
rs10936600 0.04 0.63 0.01 0.86 - - 0.03 0.64
rs1423269 -0.07 0.40 -0.13 0.08 - - -0.11 0.06
rs6595443 -0.05 0.50 -0.002 0.98 -0.15 0.39 -0.03 0.49
rs34229995 -0.15 0.43 0.03 0.89 - - -0.07 0.63
rs3132535 0.09 0.23 0.04 0.54 - - 0.07 0.21
rs9372120 -0.04 0.68 -0.11 0.14 -0.14 0.48 -0.09 0.12
rs4487645 -0.08 0.33 -0.03 0.62 - - -0.05 0.32
rs17507636 -0.01 0.91 -0.001 0.99 0.08 0.69 0.001 0.98
rs58618031 -0.09 0.27 0.03 0.68 0.20 0.30 -0.01 0.92
rs7781265 0.01 0.94 -0.01 0.95 - - 0.0001 1.00
rs1948915 0.08 0.30 -0.04 0.52 -0.34 0.06 -0.02 0.74
rs2811710 0.001 0.99 -0.02 0.78 - - -0.01 0.84
rs7577599 -0.061 0.56 0.08 0.35 0.02 0.74
German UK OncoArray Meta
Supplementary Tables 11: Relationship between SNP genotype and hyperdiploid subtype. German cases: 661, UK cases: 702, Oncoarray cases: 257, 
Meta: 1,620.  Case-only analysis; Beta values obtained from logistic regression. FISH and ploidy classification of UK and German samples were 
determined as previously described5,6.  
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SNP Risk Allele HR P- value HR P- value HR P- value HR P- value HR P- value
rs4325816 T 1.06 0.69 0.88 0.12 0.86 0.27 0.85 0.11 0.89 0.03
rs6599192 G 1.27 0.14 1.01 0.95 1.08 0.54 0.98 0.86 1.04 0.50
rs10936600 A 1.06 0.69 1.00 0.95 1.10 0.45 0.98 0.83 1.02 0.70
rs1423269 A 1.07 0.61 1.05 0.49 0.97 0.80 0.97 0.78 1.02 0.69
rs6595443 T 1.14 0.27 0.98 0.78 0.92 0.39 1.03 0.66 1.00 0.91
rs34229995 G 1.12 0.71 0.68 0.03 1.24 0.56 0.99 0.96 0.88 0.30
rs3132535 A 0.87 0.27 0.91 0.18 0.89 0.27 1.07 0.40 0.95 0.21
rs9372120 G 0.99 0.92 1.22 0.01 0.84 0.12 1.05 0.63 1.06 0.21
rs4487645 C 1.04 0.77 0.94 0.39 1.10 0.38 0.99 0.90 0.99 0.89
rs17507636 C 1.06 0.70 1.03 0.73 1.10 0.42 1.04 0.67 1.05 0.36
rs58618031 T 1.00 0.99 1.01 0.89 1.14 0.23 1.17 0.08 1.07 0.14
rs7781265 A 0.82 0.20 1.20 0.07 0.90 0.46 - - 1.02 0.77
rs1948915 C 0.96 0.73 1.02 0.83 0.96 0.68 1.04 0.59 1.01 0.89
rs2790457 G 0.88 0.40 0.91 0.21 0.92 0.48 0.94 0.55 0.92 0.08
rs13338946 C 0.76 0.03 1.02 0.75 1.07 0.54 0.91 0.25 0.96 0.32
rs7193541 T 1.01 0.94 0.94 0.34 1.05 0.61 1.06 0.43 1.00 0.96
rs34562254 A 0.91 0.51 1.07 0.46 1.40 0.05 1.13 0.33 1.09 0.16
rs11086029 T 0.98 0.89 0.82 0.01 1.06 0.57 1.05 0.62 0.94 0.17
rs6066835 C 0.92 0.63 1.03 0.77 1.13 0.48 0.90 0.41 0.99 0.87
rs139402 C 0.92 0.49 1.05 0.49 1.06 0.60 1.03 0.68 1.03 0.51
Germ-GMMG UK-MyIX UK-MyXI USA-UAMS Meta
Supplementary Table 12: Relationship between genome-wide significant SNPs genotype and patient overall survival7. Data from: 1,165 cases from 
the UK MRC Myeloma-IX trial (UK-MyIX); 877 MM cases from the UK MRC Myeloma-XI trial (UK-MyXI); 511 of the patients recruited to the German-
GWAS (GER-GMMG); 703 MM cases in the UAMS Myeloma Institute for Research and Therapy GWAS (US-UAMS). P-values calculated from Cox 
regression analysis. Data for SNPs rs2811710, rs7577599 and rs138747, or a correlated SNP (r2 >0.6) to use as proxy, were not present in the survival 
analysis.   
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rsID AA Aa aa r 2
rs58618031 7/7 58/59 83/83 0.99
rs11629542 28/31 59/63 51/53 0.91
rs6595443 53/54 74/78 41/41 0.97
UK Cases
Supplementary Table 13: Concordance between directly sequenced and imputed genotype. 
Showing SNPs which were genome-wide significant after replication. These comprised 147 
randomly selected samples from the Oncoarray case series. AA, major homozygote; Aa, 
heterozygote; aa, minor homozygote. r2 indicates Pearson product-moment correlation 
coefficient between imputed and sequenced genotype. 
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rsID Conditions
rs4325816 KASP Primer A1 GAAGGTGACCAAGTTCATGCTAACCTAGGTTGCTGGGAGAATGAT Std42
KASP Primer A2 GAAGGTCGGAGTCAACGGATTCCTAGGTTGCTGGGAGAATGAC
KASP Common Primer CATGTGACGTTGTTTTCATAAATCTCATAA
rs6595443 KASP Primer A1 GAAGGTGACCAAGTTCATGCTCCATTTCTGATAGTGTGTGTTAAAGTCT Std42plus5
KASP Primer A2 GAAGGTCGGAGTCAACGGATTCCATTTCTGATAGTGTGTGTTAAAGTCA
KASP Common Primer GTGAATGCACCTAACAGAGTATCAAAATA
rs1050976 KASP Primer A1 GAAGGTGACCAAGTTCATGCTAAGTGATGTGTTTACATTTACTGAAATGC Std42plus5
KASP Primer A2 GAAGGTCGGAGTCAACGGATTCAAGTGATGTGTTTACATTTACTGAAATGT
KASP Common Primer TTTTCTCTGTCTTCCAGCAAGACCTAAT
rs17507636 KASP Primer A1 GAAGGTGACCAAGTTCATGCTTTCACTGTAGCCATCTGTATCCC Std42plus5
KASP Primer A2 GAAGGTCGGAGTCAACGGATTCTTTCACTGTAGCCATCTGTATCCT
KASP Common Primer CCTGCTTCTTTAATTATGTATAGGGTAGAA
rs17501560 KASP Primer A1 GAAGGTGACCAAGTTCATGCTCAAGATACAACAGGTGAGACCCAA Std42plus5
KASP Primer A2 GAAGGTCGGAGTCAACGGATTAAGATACAACAGGTGAGACCCAG
KASP Common Primer TGTCCTTAATAGTTTAGTCTCCAAAATCAT
rs58618031 KASP Primer A1 GAAGGTGACCAAGTTCATGCTAGGAGGCCTCAGGAAACTTACG Std42plus15
KASP Primer A2 GAAGGTCGGAGTCAACGGATTAAGGAGGCCTCAGGAAACTTACA
KASP Common Primer CTGACATTTTCCCCACTGGCATTCAT      
rs11629542 KASP Primer A1 GAAGGTGACCAAGTTCATGCTAAGTACGTGCCTAAAAGATGGACAC Std42plus10
KASP Primer A2 GAAGGTCGGAGTCAACGGATTAAGTACGTGCCTAAAAGATGGACAG
KASP Common Primer GCCATGTCTGGGGCACTATTTCTAA
rs13338946 KASP Primer A1 GAAGGTGACCAAGTTCATGCTCGAGACTCTATCTCAATAAATGAATAAAATG Std42
KASP Primer A2 GAAGGTCGGAGTCAACGGATTGCGAGACTCTATCTCAATAAATGAATAAAATA
KASP Common Primer CACCCCACTTCATTTTTTCATAACACGTA
rs11086029 KASP Primer A1 GAAGGTGACCAAGTTCATGCTGTGGCCTCCTCTACGTTGAAAAAAAA Std42plus5
KASP Primer A2 GAAGGTCGGAGTCAACGGATTGTGGCCTCCTCTACGTTGAAAAAAAT
KASP Common Primer GGCTTCCAGGAAGAGGTAAGTAGTT
KASP Primer Sequence
rsID Sequencing Direction Sequencing Additives
rs6595443 Forward AAGGAGTCAATTCTGCAAAAAG Reverse 1M Betaine
Reverse TGCTGTTGTTGTTTGAAGTGG
rs58618031 Forward TGATAGTCATTTCTCACAAGAGCTG Forward 1M Betaine
Reverse TCTCTGTCAAAATGAAACTTACCTTC
rs11629542 Forward CCAACCTCCTCATTGTAGGG Forward 1M Betaine
Reverse AGCAAGAAACAAAGCACAGG
Sequencing Primer Sequence
Supplementary Table 14: Details of genotyping primers and reaction conditions. 
Supplementary Table 15: Details of sequencing primers and reaction conditions. 
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KASPAR conditions 
Std42 
- Hot Start: 94ºC for 15 minutes 
- Stage 1: 20 cycles 
o 94ºC for 10 seconds 
o 57ºC for 5 seconds 
o 72ºC for 10 seconds 
- Stage 2: 22 cycles 
o 94ºC for 10 seconds 
o 57ºC for 20 seconds 
o 72ºC for 40 seconds 
Std42plus5 
- Hot Start: 94ºC for 15 minutes 
- Stage 1: 20 cycles 
o 94ºC for 10 seconds 
o 57ºC for 5 seconds 
o 72ºC for 10 seconds 
- Stage 2: 22 cycles 
o 94ºC for 10 seconds 
o 57ºC for 20 seconds 
o 72ºC for 40 seconds 
- Stage 3: 5 cycles 
o 94ºC for 10 seconds 
o 57ºC for 1 minute 
Std42plus10 
- Hot Start: 94ºC for 15 minutes 
- Stage 1: 20 cycles 
o 94ºC for 10 seconds 
o 57ºC for 5 seconds 
o 72ºC for 10 seconds 
- Stage 2: 22 cycles 
o 94ºC for 10 seconds 
o 57ºC for 20 seconds 
o 72ºC for 40 seconds 
- Stage 3: 10 cycles 
o 94ºC for 10 seconds 
o 57ºC for 1 minute 
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Std42plus15 
- Hot Start: 94ºC for 15 minutes 
- Stage 1: 20 cycles 
o 94ºC for 10 seconds 
o 57ºC for 5 seconds 
o 72ºC for 10 seconds 
- Stage 2: 22 cycles 
o 94ºC for 10 seconds 
o 57ºC for 20 seconds 
o 72ºC for 40 seconds 
- Stage 3: 15 cycles 
o 94ºC for 10 seconds 
o 57ºC for 1 minute 
 
Sequencing conditions 
Std 
- 95ºC for 5 minutes 
- 25 cycles 
o 96ºC for 30 seconds 
o 50ºC for 15 seconds 
o 60ºC for 1 minute 
 
 
rsID Locus Probe chromosome Gene P SMR P HEIDI
rs6595443 5q23.2 5 CEP120 1.27×10-4 6.60×10-2
rs2807754 10p21.1 10 WAC 4.53×10-5 6.28×10-1
rs1423269 5q15 5 ELL2 7.08×10-7 5.58×10-3
rs4487645 7p15.3 7 CDCA7L 8.37×10-15 1.08×10-2
rs6090899 20q13.13 20 PREX1 4.01×10-4 5.46×10-3
Supplementary Table 16:  Summary of results from SMR analysis. We set a threshold for the 
SMR test of PSMR <1×10
-3 corresponding to a Bonferroni correction for 45 tests. For all genes 
passing this threshold we generated plots of the eQTL and GWAS associations at the locus, as 
well as plots of GWAS and eQTL effect sizes (i.e. corresponding to input for the HEIDI 
heterogeneity test). HEIDI test P values <0.05 were considered as being reflective of 
heterogeneity.  This threshold is conservative for gene discovery because it retains fewer 
genes than when correcting for multiple testing. Probes which passed the HEIDI threshold are 
highlighted in grey. 
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Locus Lead SNP
3q26.2 rs10936600 ATF2 BATF CEBPB CHD1 CTCF EBF1 ELF1 ELK1 EP300 ETS1 FOXM1 IRF4 MAX MAZ MTA3 MXI1 NFIC PML
POLR2A POLR3G POU2F2 RUNX3 RXRA SIN3A STAT5A TAF1 TBL1XR1 TBP WRNIP1 YY1
5q15 rs1423269 ATF2 BATF BCL11A BCL3 BCLAF1 BHLHE40CEBPB CHD2 EBF1 EP300 FOXM1 IKZF1 IRF4 JUND MAZ MEF2A MEF2C MTA3
MXI1 NFATC1 NFIC PML POU2F2 RELA RUNX3 SP1 SPI1 STAT3 STAT5A TBL1XR1 TBP TCF12 TCF3
8q24 rs1948915 ATF2 BCL3 BCLAF1 CEBPB CTCF EBF1 EP300 FOXM1 JUND MAZ MEF2A MEF2C MTA3 MXI1 NFIC PML POLR2ARAD21
RELA RUNX3 SIN3A SPI1 STAT3 STAT5A TBL1XR1YY1 SMC3
16p11 rs13338946 BCL3 CHD1 CHD2 CTCF EBF1 MAZ MXI1 NFIC POLR2A RELA RUNX3 SIN3A SP1 SPI1 TAF1 TCF12 WRNIP YY1
20q13 rs6066835 ATF2 BCL11A EBF1 ELF1 EP300 FOXM1 IKZF1 MEF2A MEF2C NFIC POLR2A RUNX3 SPI1 TBL1XR1USF1 WRNIP1
22q13 rs138747 ATF2 ATF3 BCL3 BHLHE40CEBPB CHD1 CHD2 EBF1 EGR1 ELF1 ELK1 EP300 FOS FOXM1 GABPA IKZF1 IRF4 MAX
MAZ MEF2C MTA3 MXI1 NFATC1 NFE2 NFIC NFYA NFYB NR2C2 PAX5 PBX3 PML POLR2A POU2F2 RELA RUNX3 SIN3A
SP1 SPI1 SRF STAT5A TAF1 TBL1XR1TBP TCF12 TCF3 USF1 USF2 WRNIP1 YY1 ZEB1 ZNF143
Transcription Factor
Supplementary Table 17: Full lists of TF binding at selected loci. TF ChIP-seq (161 factors) with Factorbook Motifs for GM12878 were downloaded from 
ENCODE8. 
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Supplementary Figure 1: Quantile-Quantile (Q-Q) plots of observed and expected χ2 values of 
association between SNP genotype and risk of multiple myeloma after imputation for the 
OncoArray cohort. λ=1.0327, λ1000=1.0209. The red line represents the null hypothesis of no true 
association. Q-Q plots for the UK, Sweden/Norway, Germany, Iceland, USA and Netherlands sets 
have been previously reported1-4. 
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Supplementary Figure 2: Population distribution of polygenic risk score (PRS) ordered by 
relative risk (RR) (compared with population median risk). PRS is based on the 23 risk SNPs. 
Vertical red lines (left to right) correspond to 1%, 10%, 50%, 90%, and 99% centile, respectively. 
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Supplementary Figure 3: Polygenic risk scores (PRS) for familial MM, sporadic MM and 
population-controls. A higher risk allele burden is seen in the familial MM compared with both 
sporadic MM and controls (difference in PRS score tested by one-sided Student’s t-test). (a) 
Based on number of risk alleles carried; (b) Calculated as the sum log-transformed odds ratios. 
The observed 1.08-fold enrichment of PRS in familial over sporadic cases is entirely compatible 
the expected familial risk attributable to the 23 risk SNPs of 1.10 given by: 
   
where pi is the frequency of the risk allele for locus i, qi = 1 − pi, and ri is the estimated per-allele 
OR. 
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Supplementary Figure 4: Q-Q plot comparing observed distributions of association statistics 
against those expected under a three-component model. Grey shaded area represents the 80% 
confidence interval. 
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  Supplementary Figure 5: Projected percentage of GWAS heritability explained for a given 
sample size. Results were obtained using a three-component model to estimate distribution of 
effect sizes. Grey shaded area represents the 95% confidence interval of the heritability 
estimate. 
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Supplementary Figure 6: The overrepresentation of histone marks in (a) naïve B and (b) KMS11 
cells at the location of new and known MM risk SNPs demonstrates that risk SNPs are enriched 
in regions of open chromatin. The red line denotes the Bonferroni corrected P-value threshold. 
a) 
b) 
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Supplementary Figure 7: The overrepresentation of transcription factor (TF) binding sites in 
GM12878 cells at the location of new and known MM risk SNPs demonstrates that risk SNPs are 
enriched in regions of B-cell relevant TF binding. The red line denotes the Bonferroni corrected P-
value threshold. 
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Supplementary Figure 8: Principal components analysis plot for the OncoArray cohort after 
removal of non-European cases. The first two principal components of the analysis are plotted. 
Cases and controls outside of the intervals 0.0155 ≤ x ≤0.019, and 0.0735 ≤ y ≤0.079 were 
excluded in order to remove individuals of non-European ancestry (grey dotted line shows the 
lower threshold of the second principal component). HapMap CEU individuals are plotted in red; 
CHB/JPT individuals are plotted in purple; YRI individuals are plotted in green. Cases are plotted 
in grey, controls plotted in black.  
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Supplementary Figure 9: Summary data-based Mendelian Randomization (SMR) analysis locus 
plot at a) 5q23.2 and b) 10p12.1. Upper panel - brown dots represent P-values for SNPs from the 
GWAS meta-analysis, diamonds represent P-values for probes from the SMR test; lower panel – 
crosses represent eQTL P-values of SNPs from MM plasma cells from 183 MRC MyIX trial patients 
(GEO: GSE21349) and 658 Heidelberg GMMG patients (EMBL-EBI: E-MTAB-2299), with genes 
passing the SMR (i.e. PSMR < 0.001) and HEIDI (i.e. PHEIDI > 0.05) tests highlighted in red. Probeset 
ID refers to Affymetrix U133 2.0 Plus Array custom chip definition file (CDF v.17) mapping to 
Entrez genes. 
 
a) 
b) 
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Supplementary Figure 10: Summary data-based Mendelian Randomization analysis effect plot 
at (a) 5q23.2 and (b) 10p12.1 Blue dots represent effect sizes of SNPs from the GWAS meta-
analysis against those from the eQTL study of MM plasma cells from 183 MRC MyIX trial patients 
(GEO: GSE21349) and 658 Heidelberg GMMG patients (EMBL-EBI: E-MTAB-2299). The top cis-
eQTL is highlighted by a red diamond. Error bars are the standard errors of the SNP effects. An 
estimate of bxy at the top cis-eQTL is represented by the orange dotted line. 
 
a) 
b) 
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Supplementary Figure 11: Heat maps outputted by ChromHMM pipeline show a) emission parameters, b) transition parameters and c) state 
functional enrichments for the KMS11 MM cell line. Columns in (c) are labelled as follows: Genome % indicates the relative percentage of the genome 
represented by each state  and relative fold enrichment for RefSeq transcription start sites (TSS); CpG Islands; 2000 base pair intervals around the TSS; 
exons; genes; transcript end sites (TES); evolutionary conservation; and nuclear lamina associated regions, respectively. Heat maps shown were used to 
assign states based on previously described rules9-11. The ChromHMM model was learned across 3 MM cell lines; JJN3, KMS11 and MM1S. 
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